---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000057"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:48:12.354825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B

## Summary
- FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.
- FY 2026 adjusted EBITDA expected >$300M; FY 2025 guidance maintained at >$135M.
- Ended Q4 2025 with >$200M cash; LINZESS list price reduced effective Jan 1, 2026.
- FDA aligned on confirmatory Phase 3 trial design for apraglutide (SBS-IF); trial to start H1 2026.
- Strategic alternatives review ongoing to maximize shareholder value.

## SEC filing metadata
- accession: 0001104659-26-000057
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/0001104659-26-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/tm2534554d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000057
- JSON: https://secwatch.observer/filing/0001104659-26-000057.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.